Tratamientos

Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment

Tratamientos

Tema

On the use of corticosteroids for 2019-nCoV pneumonia

Tratamientos

Tema

Convalescent Plasma to Treat COVID-19

Tratamientos

Tema

Recent discovery and development of inhibitors targeting coronaviruses

Tratamientos

Tema

Drug treatment options for the 2019-new coronavirus (2019- nCoV)

Tratamientos

Tema

Effective Treatment of Severe COVID-19 Patients with Tocilizumab

Tratamientos

Tema

The emergence of a novel coronavirus (SARS-CoV-2), their biology and therapeutic options

Tratamientos

Tema

The convalescent sera option for containing COVID-19

Tratamientos

Tema

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Tratamientos

Tema

Of chloroquine and COVID-19

Tratamientos

Tema

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Tratamientos

Tema

Harnessing the immune system via FcγR function in immune therapy A pathway to next- gen mAbs

Tratamientos

Tema

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Tratamientos

Tema

Reducing mortality from 2019-nCoV host-directed therapies should be an option

Tratamientos

Tema

In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus

Tratamientos

Tema

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

Tratamientos

Tema

Hydroxychloroquine and azithromycin as a treatment of COVID-19

Tratamientos

Tema

Clinical trials on drug repositioning for COVID-19 treatment

Tratamientos

Tema

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Tratamientos

Tema

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Tratamientos

Tema

Biblioteca

Tratamientos

Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment

On the use of corticosteroids for 2019-nCoV pneumonia

Convalescent Plasma to Treat COVID-19

Recent discovery and development of inhibitors targeting coronaviruses

Drug treatment options for the 2019-new coronavirus (2019- nCoV)

Effective Treatment of Severe COVID-19 Patients with Tocilizumab

The emergence of a novel coronavirus (SARS-CoV-2), their biology and therapeutic options

The convalescent sera option for containing COVID-19

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Of chloroquine and COVID-19

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Harnessing the immune system via FcγR function in immune therapy A pathway to next- gen mAbs

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Reducing mortality from 2019-nCoV host-directed therapies should be an option

In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

Hydroxychloroquine and azithromycin as a treatment of COVID-19

Clinical trials on drug repositioning for COVID-19 treatment

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Institucional

Membros

Meios

Contáctenos